

# CITATION REPORT

List of articles citing

The binding mode of epothilone A on  
alpha,beta-tubulin by electron crystallography

DOI: 10.1126/science.1099190  
Science, 2004, 305, 866-9.

**Source:** <https://exaly.com/paper-pdf/37565513/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
414	Total synthesis and biological evaluation of a C(10)/C(12)-phenylene-bridged analog of epothilone D. <b>2004</b> , 1, 1771-84		8
413	Epothilone, a Myxobacterial Metabolite with Promising Antitumor Activity. <b>2005</b> ,		5
412	Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). <b>2005</b> , 32, S3-8		84
411	Synthesis of the Salicylhalamide Core Structure from Epichlorohydrin—Laying the Foundation to Macrolactone Collections. <b>2005</b> , 2005, 728-739		13
410	Much anticipated—the bioactive conformation of epothilone and its binding to tubulin. <b>2005</b> , 44, 1298-301		52
409	The INPHARMA method: protein-mediated interligand NOEs for pharmacophore mapping. <b>2005</b> , 44, 4172-5		133
408	Lange gesucht Die bioaktive Konformation von Epothilon und seine Bindung im Tubulin. <b>2005</b> , 117, 1324-1327		8
407	The INPHARMA Method: Protein-Mediated Interligand NOEs for Pharmacophore Mapping. <b>2005</b> , 117, 4244-4247		40
406	Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. <b>2005</b> , 65, 231-40		42
405	A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. <b>2005</b> , 4, 987-95		53
404	The Taxol Pharmacophore and the T-Taxol Bridging Principle. <b>2005</b> , 4, 278-288		23
403	beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. <b>2005</b> , 65, 9406-14		35
402	Epothilone D affects cell cycle and microtubular pattern in plant cells. <b>2005</b> , 56, 2131-7		6
401	Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. <b>2005</b> , 11, 1588-96		40
400	Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. <b>2005</b> , 11, 7773-84		58
399	Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele. <b>2005</b> , 4, 1847-53		35
398	Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. <b>2005</b> , 26, 138-45		147

397	Microtubule stability studied by integral equation theory.	
396	Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin. <b>2005</b> , 44, 6844-57	30
395	Conformations of laulimalide in DMSO-d6. <b>2005</b> , 127, 12838-46	35
394	Microtubules and maps. <b>2005</b> , 71, 257-98	148
393	Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. <b>2005</b> , 48, 457-65	63
392	Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms. <b>2006</b> , 45, 185-94	31
391	Transferred Cross-Correlated Relaxation: Application to Drug/Target Complexes. <b>2008</b> , 1247-1254	
390	Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. <b>2006</b> , 5, 270-8	125
389	Cancer Drug Resistance. <b>2006</b> ,	17
388	NMR determination of the bioactive conformation of peloruside A bound to microtubules. <b>2006</b> , 128, 8757-65	60
387	C-15 thiazol-4-yl analogues of (E)-9,10-didehydroepothilone D: synthesis and cytotoxicity. <b>2006</b> , 8, 3057-9	11
386	Imidazole, oxazole and thiazole alkaloids. <b>2006</b> , 23, 464-96	203
385	Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. <b>2006</b> , 60, 1224-30	69
384	Discovering novel strategies for antimicrotubule cytotoxic therapy. <b>2006</b> , 4, 3-9	
383	Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. <b>2006</b> , 49, 1891-9	72
382	Design, total synthesis, and evaluation of novel open-chain epothilone analogues. <b>2006</b> , 8, 685-8	13
381	The T-Taxol conformation. <b>2006</b> , 49, 2478-88	31
380	A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin. <b>2006</b> , 45, 11762-75	34

379	The nucleotide switch of tubulin and microtubule assembly: a polymerization-driven structural change. <b>2006</b> , 45, 5933-8	78
378	Epothilones. <b>2006</b> ,	
377	Structure Modifications and Their Influences on Antitumor and Other Related Activities of Taxol and Its Analogs. <b>2006</b> , 73-141	2
376	3-D QSAR Studies of Microtubule Stabilizing Antimitotic Agents Towards Six Cancer Cell Lines. <b>2006</b> , 25, 952-960	6
375	The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. <b>2006</b> , 273, 3301-10	54
374	Homology modeling of tubulin: influence predictions for microtubule's biophysical properties. <b>2006</b> , 36, 35-43	23
373	Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. <b>2006</b> , 16, 221-9	125
372	The tubulin-bound conformation of discodermolide derived by NMR studies in solution supports a common pharmacophore model for epothilone and discodermolide. <b>2006</b> , 45, 7388-94	56
371	Structure-activity relationships in side-chain-modified epothilone analogues--how important is the position of the nitrogen atom?. <b>2006</b> , 1, 37-40	27
370	Molecular design and chemical synthesis of a highly potent epothilone. <b>2006</b> , 1, 41-4	41
369	Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. <b>2006</b> , 118, 2888-98	16
368	The Tubulin-Bound Conformation of Discodermolide Derived by NMR Studies in Solution Supports a Common Pharmacophore Model for Epothilone and Discodermolide. <b>2006</b> , 118, 7548-7554	14
367	Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. <b>2006</b> , 71, 292-6	19
366	Fluorinated natural products with clinical significance. <b>2006</b> , 6, 1529-43	28
365	Comparative modelling of human $\beta$ tubulin isotypes and implications for drug binding. <b>2006</b> , 17, S90-S100	39
364	Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. <b>2006</b> , 6, 207-27	11
363	A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. <b>2006</b> , 5, 287-95	144
362	Heightened sensitivity to paclitaxel in Class IVa beta-tubulin-transfected cells is lost as expression increases. <b>2007</b> , 282, 27058-27066	17

361	Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. <b>2007</b> , 13, 519-35	23
360	Epothilones in prostate cancer: review of clinical experience. <b>2007</b> , 18 Suppl 5, v22-7	11
359	Targeting the microtubules in breast cancer beyond taxanes: the epothilones. <b>2007</b> , 12, 271-80	121
358	Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. <b>2007</b> , 18 Suppl 5, v9-15	76
357	A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. <b>2007</b> , 13, 4178-84	33
356	Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. <b>2007</b> , 18 Suppl 12, xii15-20	60
355	Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. <b>2007</b> , 18, 1548-53	34
354	Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. <b>2007</b> , 18 Suppl 5, v3-8	155
353	introduction. <b>2007</b> , 18, v1-v2	
352	Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. <b>2007</b> , 7, 566-81	106
351	Amino acid substitutions at proline 220 of beta-tubulin confer resistance to paclitaxel and colcemid. <b>2007</b> , 6, 2798-806	17
350	Epothilones. <b>2007</b> ,	
349	Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation. <b>2007</b> , 257, 227-35	23
348	Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies. <b>2007</b> , 50, 2865-74	157
347	Microtubule Protocols. <b>2007</b> ,	3
346	Microtubule stability studied by three-dimensional molecular theory of solvation. <b>2007</b> , 92, 394-403	53
345	Cellular targets of natural products. <b>2007</b> , 24, 1288-310	50
344	Relationship among ligand conformations in solution, in the solid state, and at the Hsp90 binding site: geldanamycin and radicicol. <b>2007</b> , 129, 3127-34	45

- 343 The Roles of  $\beta$ Tubulin Mutations and Isotype Expression in Acquired Drug Resistance. **2007**, 3, 1176935107003002
- 342 Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution. **2007**, 46, 1864-8 82
- 341 Structural Basis of the Activity of the Microtubule-Stabilizing Agent Epothilone A Studied by NMR Spectroscopy in Solution. **2007**, 119, 1896-1900 29
- 340 CoMFA 3D-QSAR Analysis of Epothilones Based on Docking Conformation and Alignment. **2007**, 25, 453-460 4
- 339 The chemistry and biology of epothilones--the wheel keeps turning. **2007**, 2, 396-423 114
- 338 High-resolution solid-state NMR structure of an anticancer agent. **2007**, 2, 522-7 24
- 337 Synthesis and biological evaluation of (-)-dictyostatin and stereoisomers. **2007**, 63, 8537-8562 54
- 336 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. **2007**, 7, 660-669
- 335 Studying drug-tubulin interactions by X-ray crystallography. **2007**, 137, 235-43 19
- 334 Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents. **2007**, 24, 327-57 205
- 333 Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. **2007**, 25, 327-34 40
- 332 Flexible 3D pharmacophores as descriptors of dynamic biological space. **2007**, 26, 622-33 36
- 331 A new era in prostate cancer therapy: new targets and novel therapeutics. **2008**, 3, 31-39
- 330 A computational study of open-chain epothilone analogue. **2008**, 108, 967-973 4
- 329 Total synthesis and selective activity of a new class of conformationally restrained epothilones. **2008**, 14, 570-81 11
- 328 The bound conformation of microtubule-stabilizing agents: NMR insights into the bioactive 3D structure of discodermolide and dictyostatin. **2008**, 14, 7557-69 61
- 327 Microtubules: a dynamic target in cancer therapy. **2008**, 60, 165-70 146
- 326 Identification of tubulin drug binding sites and prediction of relative differences in binding affinities to tubulin isotypes using digital signal processing. **2008**, 27, 497-505 15

325	Epothilones DA fascinating family of microtubule stabilizing antitumor agents. <b>2008</b> , 11, 1336-1368	32
324	New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. <b>2008</b> , 67, 103-12	58
323	Total synthesis and evaluation of C25-benzyloxyepothilone C for tubulin assembly and cytotoxicity against MCF-7 breast cancer cells. <b>2008</b> , 18, 4904-6	7
322	Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships. <b>2008</b> , 66, 273, 275-334	5
321	The cloning and expression of alpha-tubulin in <i>Monochamus alternatus</i> . <b>2008</b> , 17, 495-504	6
320	Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. <b>2008</b> , 8 Suppl 2, S54-60	10
319	Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. <b>2008</b> , 35, S1-S14; quiz S39	66
318	Challenging patient populations in breast cancer: Taxane resistance and triple-negative receptor subtype. <b>2008</b> , 4, S40-S48	
317	Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. <b>2008</b> , 4, 483-500	32
316	Molecular modeling approaches to study the binding mode on tubulin of microtubule destabilizing and stabilizing agents. <b>2009</b> , 286, 279-328	25
315	Ixabepilone: a new antimetabolic for the treatment of metastatic breast cancer. <b>2008</b> , 42, 1252-61	9
314	Microtubule-destabilizing agents: structural and mechanistic insights from the interaction of colchicine and vinblastine with tubulin. <b>2009</b> , 286, 259-78	39
313	Anticancer Drugs Targeting Tubulin and Microtubules. <b>2008</b> , 229-249	4
312	A unique mode of microtubule stabilization induced by peloruside A. <b>2008</b> , 378, 1016-30	107
311	Conformational preferences of natural and C3-modified epothilones in aqueous solution. <b>2008</b> , 51, 1469-73	45
310	Novel cytotoxic agents: epothilones. <b>2008</b> , 65, S10-5	32
309	Evolution of polyketides: post-PKS processing in the formation of spiroketals. <b>2008</b> , 25, 651-5	9
308	Ixabepilone for the treatment of solid tumors: a review of clinical data. <b>2008</b> , 17, 423-35	15

307	Design, synthesis and biological evaluation of bridged epothilone D analogues. <b>2008</b> , 6, 4542-52	16
306	Structural studies of taxol analogues for drug discovery. <b>2008</b> , 3, 1109-22	4
305	Design and synthesis of C6-C8 bridged epothilone A. <b>2008</b> , 10, 1565-8	22
304	A natural love of natural products. <b>2008</b> , 73, 3975-84	62
303	Newer cytotoxic agents: attacking cancer broadly. <b>2008</b> , 14, 1610-7	87
302	Differential responses of mitotic spindle pole formation to microtubule-stabilizing agents epothilones A and B at low concentrations. <b>2008</b> , 7, 477-83	18
301	Epothilones in breast cancer: current status and future directions. <b>2008</b> , 8, 1299-311	7
300	The interaction of microtubules with stabilizers characterized at biochemical and structural levels. <b>2009</b> , 286, 121-49	10
299	The Plant Cytoskeleton: a Key Tool for Agro-Biotechnology. <b>2008</b> ,	15
298	Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. <b>2008</b> , 74, 1072-83	30
297	Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer. <b>2008</b> , 65, 2017-26	13
296	Tubulin and Microtubule Structures. <b>2008</b> , 211-225	1
295	Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?. <b>2008</b> , 14, 6725-9	5
294	Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. <b>2008</b> , 7, 3150-9	15
293	The epothilones: translating from the laboratory to the clinic. <b>2008</b> , 14, 1618-24	55
292	The Tubulin Binding Mode of MT Stabilizing and Destabilizing Agents Studied by NMR. <b>2009</b> , 286, 151-208	12
291	The tubulin binding mode of microtubule stabilizing agents studied by electron crystallography. <b>2009</b> , 286, 209-57	13
290	Ixabepilone for the treatment of taxane-refractory breast cancer. <b>2008</b> , 4, 333-40	3



289	Promising novel cytotoxic agents and combinations in metastatic prostate cancer. <b>2008</b> , 14, 15-9		10
288	Application of epothilones in breast cancer therapy. <b>2008</b> , 20, 634-8		5
287	Novel microtubule-targeting agents - the epothilones. <b>2008</b> , 2, 789-811		49
286	Bibliography. 374-439		
285	. <b>2009</b> ,		1
284	Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. <i>Cancer Management and Research</i> , <b>2009</b> , Volume 1, 69-77	3.6	18
283	Novel anti-tubulin cytotoxic agents for breast cancer. <b>2009</b> , 9, 175-85		20
282	Microtubule stabilising agents for cancer chemotherapy. <b>2009</b> , 19, 607-22		21
281	The efficacy and safety of ixabepilone monotherapy in the treatment of breast and gynecologic malignancies. <b>2009</b> , 8, 81-8		6
280	Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). <b>2009</b> , 24, 511-22		20
279	Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. <b>2009</b> , 20, 492-7		44
278	Helical growth of the Arabidopsis mutant tortifolia2 does not depend on cell division patterns but involves handed twisting of isolated cells. <b>2009</b> , 21, 2090-106		66
277	The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. <b>2009</b> , 15, 95-106		6
276	Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. <b>2009</b> , 31, 1619-40		48
275	Epothilone analogues with benzimidazole and quinoline side chains: chemical synthesis, antiproliferative activity, and interactions with tubulin. <b>2009</b> , 15, 10144-57		25
274	Making epothilones fluoresce: design, synthesis, and biological characterization of a fluorescent N12-aza-epothilone (azathilone). <b>2009</b> , 10, 2513-21		10
273	Cyclostreptin and microtubules: is a low-affinity binding site required?. <b>2010</b> , 11, 101-9		12
272	Toward docking-based virtual screening for discovering antitubulin agents by targeting taxane and colchicine binding sites. <b>2009</b> , 4, 161-3		8

271	Recent advances in the study of the bioactive conformation of taxol. <b>2009</b> , 4, 719-31	35
270	De(side chain) model of epothilone: bioconformer interconversions DFT study. <b>2009</b> , 15, 859-69	6
269	On and around microtubules: an overview. <b>2009</b> , 43, 177-91	141
268	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <b>2009</b> , 11, 787-98	31
267	Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. <b>2009</b> , 64, 1029-38	7
266	Fragment-Based QSAR and Molecular Modeling Studies on a Series of Discodermolide Analogs as Microtubule-Stabilizing Anticancer Agents. <b>2009</b> , 28, 325-337	16
265	Possible binding site for paclitaxel at microtubule pores. <b>2009</b> , 276, 2701-12	26
264	Total synthesis and evaluation of 22-(3-azidobenzoyloxy)methyl epothilone C for photoaffinity labeling of beta-tubulin. <b>2009</b> , 19, 3293-6	4
263	Synthesis and SAR of C12-C13-oxazoline derivatives of epothilone A. <b>2009</b> , 19, 3760-3	19
262	Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. <b>2009</b> , 49, 424-36	49
261	Structural and biological characterization of the tubulin interaction with dinitroanilines. <b>2009</b> , 43, 267-282	10
260	Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. <b>2009</b> , 8, 2086-95	368
259	Chapter 15 Case History: Discovery of Ixabepilone (IXEMPRATM), a First-in-Class Epothilone Analog for Treatment of Metastatic Breast Cancer. <b>2009</b> , 301-322	9
258	Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. <b>2009</b> , 45, 2940-6	21
257	New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. <b>2009</b> , 52, 7512-27	70
256	Macrolide-based microtubule-stabilizing agents - chemistry and structure-activity relationships. <b>2009</b> , 286, 1-72	6
255	Dinitroaniline Interactions with Tubulin: Genetic and Computational Approaches to Define the Mechanisms of Action and Resistance. <b>2008</b> , 327-349	3
254	New sources of chemical diversity inspired by biosynthesis: rational design of a potent epothilone analogue. <b>2009</b> , 11, 3186-9	16

253	Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. <b>2009</b> , 6, 85-92	20
252	General Aspects. <b>2009</b> , 5-28	1
251	Preclinical pharmacology and structure-activity studies of epothilones. <b>2009</b> , 90, 157-220	2
250	Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. <b>2010</b> , 16, 1452-65	35
249	Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone. <b>2010</b> , 33, 561-7	2
248	MMHD [(S,E)-2-methyl-1-(2-methylthiazol-4-yl) hexa-1,5-dien-ol], a novel synthetic compound derived from epothilone, suppresses nuclear factor-kappaB-mediated cytokine expression in lipopolysaccharide-stimulated BV-2 microglia. <b>2010</b> , 112, 158-66	14
247	Paclitaxel and Epothilone Analogues, Anticancer Drugs. <b>2010</b> , 243-267	2
246	Microtubule targeting agents: from biophysics to proteomics. <b>2010</b> , 67, 1089-104	55
245	Functional significance may underlie the taxonomic utility of single amino acid substitutions in conserved proteins. <b>2010</b> , 70, 395-402	7
244	Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site. <b>2010</b> , 12, 113-7	39
243	A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. <b>2010</b> , 119, 663-71	36
242	Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. <b>2010</b> , 10, 213	69
241	Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilones. <b>2010</b> , 5, 35-40	22
240	The binding mode of side chain- and C3-modified epothilones to tubulin. <b>2010</b> , 5, 911-20	12
239	Molecular recognition of peloruside A by microtubules. The C24 primary alcohol is essential for biological activity. <b>2010</b> , 11, 1669-78	21
238	The Tubulin-Bound Structure of the Antimitotic Drug Tubulysin. <b>2010</b> , 122, 4919-4922	7
237	Interaction of Epothilone B (Patupilone) with Microtubules as Detected by Two-Dimensional Solid-State NMR Spectroscopy. <b>2010</b> , 122, 7666-7669	3
236	The tubulin-bound structure of the antimitotic drug tubulysin. <b>2010</b> , 49, 4809-12	20

235	Interaction of epothilone B (patupilone) with microtubules as detected by two-dimensional solid-state NMR spectroscopy. <b>2010</b> , 49, 7504-7		31
234	Conformations of stevastelin C3 analogs: computational deconvolution of NMR data reveals conformational heterogeneity and novel motifs. <b>2010</b> , 93, 968-76		3
233	Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses. <b>2010</b> , 17, 243-53		19
232	Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. <b>2010</b> , 17, 725-34		106
231	Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. <b>2010</b> , 20, 4578-81		34
230	Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. <b>2010</b> , 16, 252-63		27
229	Microtubules and resistance to tubulin-binding agents. <b>2010</b> , 10, 194-204		742
228	. <b>2010</b> ,		25
227	Ixabepilone development across the breast cancer continuum: a paradigm shift. <i>Cancer Management and Research</i> , <b>2010</b> , 2, 169-79	3.6	5
226	Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer. <b>2010</b> , 2, 13-23		
225	The binding of vinca domain agents to tubulin: structural and biochemical studies. <b>2010</b> , 95, 373-90		18
224	Managing patients with advanced and metastatic breast cancer. <b>2010</b> , 14, 313-23		7
223	Natural products in structure-assisted design of molecular cancer therapeutics. <b>2010</b> , 16, 1718-41		16
222	Cryoelectron microscopy applications in the study of tubulin structure, microtubule architecture, dynamics and assemblies, and interaction of microtubules with motors. <b>2010</b> , 483, 121-42		11
221	Present and future evolution of advanced breast cancer therapy. <b>2010</b> , 12 Suppl 2, S1		40
220	New microtubule-inhibiting anticancer agents. <b>2010</b> , 19, 329-43		41
219	The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. <b>2010</b> , 67, 136-43		62
218	Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. <b>2010</b> , 10 Suppl 2, S30-40		

217	The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [ $^3$ H]peloruside A. <b>2010</b> , 50, 219-28	33
216	The discodermolide hairpin structure flows from conformationally stable modular motifs. <b>2010</b> , 53, 155-65	23
215	Total synthesis and evaluation of C26-hydroxyepothilone D derivatives for photoaffinity labeling of beta-tubulin. <b>2010</b> , 75, 86-94	10
214	Quantum-chemical study on the bioactive conformation of epothilones. <b>2010</b> , 50, 2176-90	5
213	Microbial-based therapy of cancer: current progress and future prospects. <b>2010</b> , 1, 178-90	50
212	Conformational ensembles of flexible beta-turn mimetics in DMSO-d <sub>6</sub> . <b>2010</b> , 8, 2103-16	19
211	Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. <b>2010</b> , 12 Suppl 2, S2	131
210	Novel epothilone lactones by an unusual diversion of the Grubbs' metathesis reaction. <b>2010</b> , 46, 2019-21	6
209	Signposts to Chiral Drugs. <b>2011</b> ,	3
208	Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1. <b>2011</b> , 10, 269-76	28
207	12-Aza-Epothilones. <b>2011</b> , 209-223	
206	The structure of bacterial S-layer proteins. <b>2011</b> , 103, 73-130	49
205	New insights into the mechanisms of cytomotive actin and tubulin filaments. <b>2011</b> , 292, 1-71	48
204	Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. <b>2011</b> , 71, 3-10	314
203	Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. <b>2011</b> , 71, 6019-29	341
202	Old friends in new guise: repositioning of known drugs with structural bioinformatics. <b>2011</b> , 12, 312-26	106
201	What tubulin drugs tell us about microtubule structure and dynamics. <b>2011</b> , 22, 916-26	68
200	Epothilones in prostate cancer. <b>2011</b> , 29, 358-65	4

199	Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. <b>2011</b> , 54, 8394-406	58
198	Design, overexpression, and purification of polymerization-blocked yeast $\beta$ tubulin mutants. <b>2011</b> , 50, 8636-44	60
197	Prostate Cancer: Current and Emerging Therapies. <b>2011</b> ,	1
196	QM and QM/MD simulations of the Vinca alkaloids docked to tubulin. <b>2011</b> , 30, 54-66	2
195	Ixabepilone: clinical role in metastatic breast cancer. <b>2011</b> , 11, 139-45	17
194	Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach. <b>2011</b> , 6, 789-99	41
193	Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. <b>2011</b> , 25, 443-54	41
192	Molecular dynamics modeling of tubulin C-terminal tail interactions with the microtubule surface. <b>2011</b> , 79, 2968-82	30
191	C6-C8 bridged epothilones: consequences of installing a conformational lock at the edge of the macrocycle. <b>2011</b> , 17, 14792-804	8
190	Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization. <b>2011</b> , 46, 3519-25	13
189	Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site. <b>2011</b> , 29, 947-55	45
188	Targeting $\beta$ II-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. <b>2011</b> , 11, 719-28	19
187	A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos. <b>2011</b> , 10, 994-1006	21
186	Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction. <b>2011</b> , 286, 41466-41478	68
185	Management options in triple-negative breast cancer. <b>2011</b> , 5, 175-99	29
184	Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. <b>2011</b> , 286, 11765-78	51
183	Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. <b>2012</b> , 19, 91-105	12
182	Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?. <b>2012</b> , 23, 547-555	39

181	Analogue-based drug discovery: Contributions to medicinal chemistry principles and drug design strategies. Microtubule stabilizers as a case in point (Special Topic Article). <b>2012</b> , 84, 1479-1542	8
180	Seek and destroy: the use of natural compounds for targeting the molecular roots of cancer. <b>2012</b> , 13, 1072-82	12
179	Effect of epothilone B on cell cycle, metabolic activity, and apoptosis induction on human epithelial cancer cells-under special attention of combined treatment with ionizing radiation. <b>2012</b> , 30, 593-603	1
178	Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile. <b>2012</b> , 30, 559-73	11
177	Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. <b>2012</b> , 30, 2294-302	9
176	Identification of a class of novel tubulin inhibitors. <b>2012</b> , 55, 3425-35	24
175	Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. <b>2012</b> , 55, 8979-96	130
174	4.6 Tubulin and Microtubule Structure: Mechanistic Insights into Dynamic Instability and Its Biological Relevance. <b>2012</b> , 72-92	3
173	Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice. <b>2012</b> , 123, 982-96	25
172	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents. <b>2012</b> , 20, 6285-95	14
171	Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells. <b>2012</b> , 1489, 121-32	13
170	Molecular simulations of drug-receptor complexes in anticancer research. <b>2012</b> , 4, 1961-70	3
169	NMR in natural products: understanding conformation, configuration and receptor interactions. <b>2012</b> , 29, 536-54	24
168	Patupilone and ixabepilone: the effect of a point structural change on the exo-endo conformational profile. <b>2012</b> , 116, 7605-17	3
167	The structures of type I polyketide synthases. <b>2012</b> , 29, 1050-73	207
166	Interfacial inhibitors: targeting macromolecular complexes. <b>2011</b> , 11, 25-36	166
165	Understanding the basis of drug resistance of the mutants of $\beta$ -tubulin dimer via molecular dynamics simulations. <b>2012</b> , 7, e42351	34
164	Dynamics of tumor hypoxia in response to patupilone and ionizing radiation. <b>2012</b> , 7, e51476	11

163	Novel drugs targeting microtubules: the role of epothilones. <b>2012</b> , 18, 2793-803	26
162	Macrocycles in new drug discovery. <b>2012</b> , 4, 1409-38	284
161	Comparative binding energy (COMBINE) analysis supports a proposal for the binding mode of epothilones to $\beta$ -tubulin. <b>2012</b> , 7, 836-43	11
160	Differentiating between models of epothilone binding to microtubules using tubulin mutagenesis, cytotoxicity, and molecular modeling. <b>2012</b> , 7, 1580-6	6
159	Synthesis of Triazole-Epothilones by Using Cu <sub>2</sub> O Nanoparticles to Catalyze 1,3-Dipolar Cycloaddition. <b>2012</b> , 2012, 500-508	15
158	Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. <b>2012</b> , 32, 1220-62	124
157	Radiosensitizing effect of epothiloneB on human epithelial cancer cells. <b>2012</b> , 188, 177-84	11
156	Molecular dynamics simulation and density functional theory studies on the active pocket for the binding of paclitaxel to tubulin. <b>2012</b> , 18, 377-91	15
155	Natural Products and Cancer Drug Discovery. <b>2013</b> ,	5
154	Electron Crystallography of Soluble and Membrane Proteins. <b>2013</b> ,	6
153	Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization. <b>2013</b> , 82, 12-21	13
152	Similarity-based virtual screening for microtubule stabilizers reveals novel antimitotic scaffold. <b>2013</b> , 44, 188-96	14
151	Total synthesis of epothilone D: the nerol/macroaldolization approach. <b>2013</b> , 78, 10588-95	23
150	Epothilone D and its 9-Methyl analogues: combinatorial syntheses, conformation, and biological activities. <b>2013</b> , 68, 321-32	6
149	Enantioselective effects of (+)- and (-)-citronellal on animal and plant microtubules. <i>Journal of Natural Products</i> , <b>2013</b> , 76, 1598-604	4-9 8
148	Phase I trial of dasatinib and ixabepilone in patients with solid tumors. <b>2013</b> , 31, 92-8	7
147	Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. <b>2013</b> , 56, 123-49	91
146	Molecular mechanism of action of microtubule-stabilizing anticancer agents. <i>Science</i> , <b>2013</b> , 339, 587-90	33-3 345



145	Design and synthesis of cyclopropylamide analogues of combretastatin-A4 as novel microtubule-stabilizing agents. <b>2013</b> , 56, 685-99	54
144	Direct modulation of microtubule stability contributes to anthracene general anesthesia. <b>2013</b> , 135, 5389-98	35
143	Tubulin: an example of targeted chemotherapy. <b>2013</b> , 5, 339-52	59
142	The binding sites of microtubule-stabilizing agents. <b>2013</b> , 20, 301-15	78
141	Natural Product Scaffolds in Cancer Therapy. <b>2013</b> , 123-173	
140	Microtubule stabilising agents and ionising radiation: multiple exploitable mechanisms for combined treatment. <b>2013</b> , 49, 245-53	12
139	ATP transport through VDAC and the VDAC-tubulin complex probed by equilibrium and nonequilibrium MD simulations. <b>2013</b> , 52, 9246-56	45
138	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <b>2013</b> , 2013, 103830	16
137	Relating nucleotide-dependent conformational changes in free tubulin dimers to tubulin assembly. <b>2013</b> , 99, 282-91	10
136	Conventional Cancer Treatment. <b>2013</b> ,	6
135	Epothilones: From discovery to clinical trials. <b>2014</b> , 14, 2312-21	37
134	Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. <b>2014</b> , 7, 575-85	33
133	. <b>2014</b> ,	15
132	The free energy profile of tubulin straight-bent conformational changes, with implications for microtubule assembly and drug discovery. <b>2014</b> , 10, e1003464	27
131	Intramolecular oxo-Diels-Alder rearrangement in collisionally activated dissociation of protonated ions of a macrocyclic molecule: triazole-epothilone dimer. <b>2014</b> , 49, 755-62	1
130	CHAPTER 3:Epothilones. <b>2014</b> , 78-108	3
129	Development of other microtubule-stabilizer families: the epothilones and their derivatives. <b>2014</b> , 25, 599-609	24
128	Phase II trial of patupilone in patients with brain metastases from breast cancer. <b>2014</b> , 16, 579-83	21

127	Targeting microtubules by natural agents for cancer therapy. <b>2014</b> , 13, 275-84	310
126	Studies of (-)-pironetin binding to $\beta$ -tubulin: conformation, docking, and molecular dynamics. <b>2014</b> , 79, 3752-64	18
125	Indicine N-oxide binds to tubulin at a distinct site and inhibits the assembly of microtubules: a mechanism for its cytotoxic activity. <b>2014</b> , 225, 66-77	19
124	Natural products in medicine: transformational outcome of synthetic chemistry. <b>2014</b> , 57, 9292-308	70
123	Lead Discovery and Lead Modification. <b>2014</b> , 19-122	5
122	The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent. <b>2014</b> , 47, 2682-91	29
121	New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. <b>2014</b> , 57, 6531-52	57
120	Synthesis of isotopically labeled epothilones. <b>2014</b> , 57, 78-81	3
119	Chemistry and Biology of Epothilones. <b>2014</b> , 81-126	1
118	Molecular recognition of epothilones by microtubules and tubulin dimers revealed by biochemical and NMR approaches. <b>2014</b> , 9, 1033-43	27
117	Nanoways to overcome docetaxel resistance in prostate cancer. <b>2014</b> , 17, 13-23	61
116	High-resolution microtubule structures reveal the structural transitions in $\beta$ -tubulin upon GTP hydrolysis. <b>2014</b> , 157, 1117-29	422
115	Small molecule modulators of protein-protein interactions: selected case studies. <b>2014</b> , 114, 4640-94	65
114	Violacein induces p44/42 mitogen-activated protein kinase-mediated solid tumor cell death and inhibits tumor cell migration. <b>2015</b> , 12, 1443-8	13
113	Synthesis and Biological Evaluation of Novel Epothilone B Side Chain Analogues. <b>2015</b> , 10, 1974-9	8
112	Study on Molecular Recognition between Euphorbia Factor L713283 and $\beta$ -Tubulin via Molecular Simulation Methods. <b>2015</b> , 2015, 1-13	0
111	Structural insight into epothilones antitumor activity based on the conformational preferences and tubulin binding modes of epothilones A and B obtained from molecular dynamics simulations. <b>2015</b> , 33, 789-803	5
110	The design, synthesis, in vitro biological evaluation and molecular modeling of novel benzenesulfonate derivatives bearing chalcone moieties as potent anti-microtubulin polymerization agents. <b>2015</b> , 5, 23767-23777	13

109	Emerging microtubule targets in glioma therapy. <b>2015</b> , 22, 49-72	28
108	Cryo-EM: A Unique Tool for the Visualization of Macromolecular Complexity. <b>2015</b> , 58, 677-89	218
107	Selected hybrid natural products as tubulin modulators. <b>2015</b> , 94, 497-508	11
106	Restoration of Microtubule Interaction and Cytotoxicity in D-seco Taxanes upon Incorporation of 20-Hydroxymethyl-4-allyloxy Groups. <b>2015</b> , 17, 6098-101	6
105	Anticancer Drugs Targeting Tubulin and Microtubules. <b>2015</b> , 359-390	1
104	Structural basis for drug resistance conferred by $\beta$ tubulin mutations: a molecular modeling study on native and mutated tubulin complexes with epothilone B. <b>2015</b> , 33, 2530-40	6
103	New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. <b>2015</b> , 58, 5789-807	38
102	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. <b>2015</b> , 11, 1177-85	8
101	Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents. <b>2015</b> , 23, 3774-80	27
100	Conformation-activity relationships of polyketide natural products. <b>2015</b> , 32, 1183-206	41
99	Mechanism of action of ixabepilone and its interactions with the $\beta$ II-tubulin isotype. <b>2015</b> , 76, 1013-24	29
98	Binding of dihydroxynaphthyl aryl ketones to tubulin colchicine site inhibits microtubule assembly. <b>2015</b> , 466, 418-25	7
97	Heterologous Production of the Marine Myxobacterial Antibiotic Haliangicin and Its Unnatural Analogues Generated by Engineering of the Biochemical Pathway. <b>2016</b> , 6, 22091	22
96	Inhibition of cancer cell growth and migration by dihydroxynaphthyl aryl ketones. <b>2016</b> , 12, 237-242	2
95	Macrolactam analogues of macrolide natural products. <b>2016</b> , 14, 11301-11316	7
94	Targeting the Bacterial Division Protein FtsZ. <b>2016</b> , 59, 6975-98	73
93	Characterizing the Epothilone Binding Site on $\beta$ Tubulin by Photoaffinity Labeling: Identification of $\beta$ Tubulin Peptides TARGSQY and TSRGSQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin. <b>2016</b> , 59, 3499-514	17
92	Microtubule-stabilizing agents: New drug discovery and cancer therapy. <b>2016</b> , 162, 134-43	51

91	Structural features and lipid binding domain of tubulin on biomimetic mitochondrial membranes. <b>2017</b> , 114, E3622-E3631	30
90	Molecular Basis for Mitochondrial Signaling. <b>2017</b> ,	3
89	12,13-Aziridinyl Epothilones. Stereoselective Synthesis of Trisubstituted Olefinic Bonds from Methyl Ketones and Heteroaromatic Phosphonates and Design, Synthesis, and Biological Evaluation of Potent Antitumor Agents. <b>2017</b> , 139, 7318-7334	28
88	Molecular modeling study on the tubulin-binding modes of epothilone derivatives: Insight into the structural basis for epothilones activity. <b>2017</b> , 90, 1247-1259	3
87	Cell Division Machinery and Disease. <b>2017</b> ,	2
86	Clinical Development of Anti-mitotic Drugs in Cancer. <b>2017</b> , 1002, 125-152	18
85	Exploring $\beta$ Tubulin Inhibitors from Plant Origin using Computational Approach. <b>2017</b> , 28, 230-241	9
84	Development and Biological Evaluation of Imidazothiazole propenones as Tubulin Inhibitors that Effectively Triggered Apoptotic Cell Death in Alveolar Lung Cancer Cell Line. <b>2017</b> , 2, 6480-6487	6
83	Exposure to cigarette smoke extract and lipopolysaccharide modifies cytoskeleton organization in bronchial epithelial cells. <b>2017</b> , 43, 347-358	15
82	Natural and Nature-Inspired Macrocycles. <b>2017</b> , 77-100	1
81	Tubulin and Microtubule Structure: Mechanistic Insights Into Dynamic Instability and Its Biological Relevance. <b>2017</b> ,	0
80	The Application of REDOR NMR to Understand the Conformation of Epothilone B. <b>2017</b> , 18,	3
79	Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders. <b>2017</b> , 18,	18
78	Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery. <i>Journal of Natural Products</i> , <b>2018</b> , 81, 703-721	4-9 23
77	Automated identification of structurally heterogeneous and patentable antiproliferative hits as potential tubulin inhibitors. <b>2018</b> , 92, 1161-1170	1
76	New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors. <b>2018</b> , 152, 283-297	22
75	Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. <b>2018</b> , 885-906.e8	1
74	Microtubule structure by cryo-EM: snapshots of dynamic instability. <b>2018</b> , 62, 737-751	39

73 Preface. ix-x

72 Physics as a Basis for Describing Biological Systems. 1-24

71 Errors, Units, and Scaling Laws. 25-60

70 Motions and Oscillations. 61-97

69 Resonances and Waves. 98-150

68 Optics, Light, and Colors. 151-216

67 Forces and Newton's Laws of Motion. 217-259

66 Continuum Mechanics. 260-309

65 Heat, Temperature, and Entropy. 310-362

64 Electrical Charges and Currents. 363-400

63 Magnetism. 401-419

62 Mathematical Tools. 420-440

61 Solutions to Quizzes. 441-443

60 References. 444-446

59 Index. 447-452

58 Repositioning Microtubule Stabilizing Drugs for Brain Disorders. **2018**, 12, 226

35

57 Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton. **2018**, 28, 776-792

182

56 Towards modern anticancer agents that interact with tubulin. **2019**, 131, 58-68

20

55	Insights into the flexibility of the T3 loop and GTPase activating protein (GAP) domain of dimeric $\beta$ and $\alpha$ tubulins from a molecular dynamics perspective. <b>2019</b> , 82, 37-43	1
54	Conformational Properties of the Chemotherapeutic Drug Analogue Epothilone A: How to Model a Flexible Protein Ligand Using Scarcely Available Experimental Data. <b>2019</b> , 59, 2218-2230	2
53	Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. <b>2019</b> , 39, 1398-1426	48
52	Computational Prediction of the Mode of Binding of Antitumor Lankacidin C to Tubulin. <b>2019</b> , 4, 4461-4471	10
51	3. Structural investigations of membrane-associated proteins by neutron reflectometry. <b>2019</b> , 87-130	5
50	Double-sides sticking mechanism of vinblastine interacting with $\beta$ tubulin to get activity against cancer cells. <b>2019</b> , 37, 4080-4091	12
49	Antitubulin sulfonamides: The successful combination of an established drug class and a multifaceted target. <b>2019</b> , 39, 775-830	16
48	New pyranosyl cembranoid diterpenes from <i>Sarcophyton trocheliophorum</i> . <b>2019</b> , 33, 24-33	8
47	Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics. <b>2020</b> , 60, 1528-1539	14
46	Stabilization of microtubules improves cognitive functions and axonal transport of mitochondria in Alzheimer's disease model mice. <b>2020</b> , 96, 223-232	4
45	Applications of Wittig Reaction in the Total Synthesis of Natural Macrolides. <b>2020</b> , 5, 9654-9690	6
44	ROS-Responsive Nanoparticles Formed from RGD-Epothilone B Conjugate for Targeted Cancer Therapy. <b>2020</b> , 12, 18301-18308	20
43	An overview on anti-tubulin agents for the treatment of lymphoma patients. <b>2020</b> , 211, 107552	11
42	High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design. <b>2021</b> , 534, 330-336	3
41	Microtubule-targeting agents and neurodegeneration. <b>2021</b> , 26, 604-615	3
40	Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. <b>2021</b> , 54, 100742	40
39	Epothilones A and B: The 16-Membered Natural Macrolides as a Fascinating Template for Antibreast Cancer Drug Discovery. <b>2021</b> , 7-28	
38	Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. <b>2021</b> , 421, 115534	5

37	Integrating Resonant Recognition Model and Stockwell Transform for Localization of Hotspots in Tubulin. <b>2021</b> , 20, 345-353	1
36	Peroxide- and transition metal-free electrochemical synthesis of epoxy ketones. <b>2021</b> , 19, 2481-2486	0
35	Spatial Distribution Of Tubulin Mutations Conferring Resistance To Antimicrotubular Compounds. <b>2008</b> , 397-417	1
34	Resistance To Taxanes. <b>2006</b> , 329-358	9
33	Microtubule Stabilizing Agents. <b>2008</b> , 307-336	1
32	Resistance to Microtubule-Targeting Drugs. <b>2008</b> , 357-394	1
31	Microtubules as a Target in Cancer Therapy. <b>2012</b> , 203-221	4
30	Lipids in Regulation of the Mitochondrial Outer Membrane Permeability, Bioenergetics, and Metabolism. <b>2017</b> , 185-215	5
29	Taxanes and Epothilones in Cancer Treatment. <b>2011</b> , 39-60	1
28	Microtubule-targeting agents and their impact on cancer treatment. <b>2020</b> , 99, 151075	35
27	Specific $\beta$ -tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. <b>2011</b> , 6, e21717	32
26	Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.. <b>2019</b> , 2, 82-106	6
25	A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel. <b>2011</b> , 8, 325-54	3
24	Other Novel Therapies. <b>2006</b> , 281-289	
23	Chemotherapy for Metastatic Breast Cancer. <b>2009</b> , 1233-1261	1
22	Beyond MVAC: New and Improved Chemotherapeutics. <b>2009</b> , 247-262	
21	Glycoconjugates. <b>2011</b> ,	
20	Microtubules, Drug Resistance, and Tumorigenesis. <b>2012</b> , 223-240	

19	Establishment of Sorangium cellulosum So0157-2 Proteome Database Using Optimized Two-dimensional Electrophoresis Protocol*. <b>2012</b> , 39, 86-94		
18	Structure-function insights of membrane and soluble proteins revealed by electron crystallography. <b>2013</b> , 955, 519-26		
17	Introductory Physics for Biological Scientists. <b>2018</b> ,		
16	Advantages of a unique DNA-based vaccine in comparison to paclitaxel in treatment of an established intracerebral breast cancer in mice. <b>2006</b> , 4A, 163-170		1
15	The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. <b>2007</b> , 3, 159-81		27
14	Ixabepilone (ixemptra), a therapeutic option for locally advanced or metastatic breast cancer. <i>P and T</i> , <b>2008</b> , 33, 523-31	1.4	10
13	Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. <i>Cancer Management and Research</i> , <b>2009</b> , 1, 69-77	3.6	7
12	Comparison of Epothilone and Taxol Binding in Yeast Tubulin using Molecular Modeling. <i>Avicenna Journal of Medical Biotechnology</i> , <b>2011</b> , 3, 167-75	1.4	10
11	Microtubule-Inspired Functionalization of Carbon Nanotubes: A Biomimetic Carrier Design.		
10	Microtentacle Formation in Ovarian Carcinoma.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
9	Microtubule-inspired functionalization of carbon nanotubes: a biomimetic carrier design. <i>Molecular Systems Design and Engineering</i> , <b>2022</b> , 7, 330-349	4.6	0
8	Utilization of Photoaffinity Labeling to Investigate Binding of Microtubule Stabilizing Agents to P-Glycoprotein and $\beta$ Tubulin.. <i>Journal of Natural Products</i> , <b>2022</b> ,	4.9	
7	Microtubules as Regulators of Neural Network Shape and Function: Focus on Excitability, Plasticity and Memory.. <i>Cells</i> , <b>2022</b> , 11,	7.9	0
6	Epoxides: Developability as active pharmaceutical ingredients and biochemical probes.. <i>Bioorganic Chemistry</i> , <b>2022</b> , 125, 105862	5.1	0
5	Accelerating the 3D reference interaction site model theory of molecular solvation with treecode summation and cut-offs.. <i>Journal of Computational Chemistry</i> , <b>2022</b> ,	3.5	0
4	Natural products in chemotherapy of cancers. <b>2022</b> , 507-546		
3	The Cytoprotective, Cytotoxic and Nonprotective Functional Forms of Autophagy Induced by Microtubule Poisons in Tumor CellsImplications for Autophagy Modulation as a Therapeutic Strategy. <i>Biomedicines</i> , <b>2022</b> , 10, 1632	4.8	2
2	Design and Introducing Quaternary Ammonium Hydroxide-Functionalized Graphene Oxide Quantum Dots as an Efficient Pseudo-Homogeneous Catalyst for Epoxidation of $\beta$ Unsaturated Ketones.		0



1 Microtubule Inhibitors. 1-18

o